Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Scher

Showing results (611-620 of 692) with videos related to

Pageof 70
Sort By:
European Urology|October 29, 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 StudiesJoaquim Bellmunt, Thian Kheoh, Margaret K Yu, et al.
The Journal of Clinical Investigation|June 9, 2007
Improved prediction of prostate cancer recurrence through systems pathologyCarlos Cordon-Cardo, Angeliki Kotsianti, David A Verbel, et al.
European Urology|December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain EndpointEthan M Basch, Mark Scholz, Johann S de Bono, et al.
Cancer Cell|November 21, 2017
Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration ResistanceShipra Shukla, Joanna Cyrta, Devan A Murphy, et al.
Journal of Translational Medicine|July 4, 2012
Considerations in the development of circulating tumor cell technology for clinical useDavid R Parkinson, Nicholas Dracopoli, Brenda Gumbs Petty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamideD E Rathkopf, M R Smith, C J Ryan, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2018
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and BiomarkersHimisha Beltran, Clara Oromendia, Daniel C Danila, et al.
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Molecular Cancer Therapeutics|August 10, 2004
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancerDaniel E H Afar, Vinay Bhaskar, Eric Ibsen, et al.
Pageof 70

Showing results (611-620 of 692) with videos related to

Sort By:
Pageof 70
European Urology|October 29, 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 StudiesJoaquim Bellmunt, Thian Kheoh, Margaret K Yu, et al.
The Journal of Clinical Investigation|June 9, 2007
Improved prediction of prostate cancer recurrence through systems pathologyCarlos Cordon-Cardo, Angeliki Kotsianti, David A Verbel, et al.
European Urology|December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain EndpointEthan M Basch, Mark Scholz, Johann S de Bono, et al.
Cancer Cell|November 21, 2017
Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration ResistanceShipra Shukla, Joanna Cyrta, Devan A Murphy, et al.
Journal of Translational Medicine|July 4, 2012
Considerations in the development of circulating tumor cell technology for clinical useDavid R Parkinson, Nicholas Dracopoli, Brenda Gumbs Petty, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 22, 2017
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamideD E Rathkopf, M R Smith, C J Ryan, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 21, 2018
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and BiomarkersHimisha Beltran, Clara Oromendia, Daniel C Danila, et al.
European Urology|August 20, 2020
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term SurvivorsKarim Fizazi, Charles G Drake, Tomasz M Beer, et al.
Molecular Cancer Therapeutics|August 10, 2004
Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancerDaniel E H Afar, Vinay Bhaskar, Eric Ibsen, et al.
Pageof 70